Join our daily newsletter At The Bell to receive exclusive market insights
- Anatara Lifesciences (ANR) receives ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome (IBS) and psychological functioning trials
- The expansion comes after the company was facing a significant screening failure rate due to the strict eligibility criteria
- The approval will expand eligibility to all IBS subtypes, as opposed to only the constipation subtype
- The IBS results will not be influenced by the change, but the psychological functioning study reporting is now expected in early next year
- Shares are trading in the grey at 6.3 cents each at 2:40 pm AEST
Anatara Lifesciences (ANR) has received ethics approval to expand eligibility criteria for its Irritable Bowel Syndrome (IBS) and psychological functioning trials.
The expansion comes after the company was facing a significant screening failure rate due to the strict eligibility criteria.
The approval will expand eligibility to all IBS subtypes, as opposed to only the constipation subtype.
This allows for 300 potential participants, who previously weren’t able to be enrolled in the trial due to not having diarrhoea predominant IBS.
The psychological functioning trials will now be able to recruit participants from the mild to moderate range of scores on the Depression Anxiety Stress Scale.
ANR said the change is not expected to influence the timeline for the IBS results. However, the psychological functioning study reporting is now expected in early next year, as opposed to late this year.
“The delays have been frustrating for all concerned including our shareholders and these should represent the final modifications,” Chair David Brooks said.
Shares were trading in the grey at 6.3 cents each at 2:40 pm AEST.
